Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.
Identifieur interne : 000809 ( Main/Exploration ); précédent : 000808; suivant : 000810Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.
Auteurs : Jonathan P. Wong [Canada] ; Paul Ditullio [États-Unis] ; Steve Parkinson [États-Unis]Source :
- Future microbiology [ 1746-0921 ] ; 2015.
English descriptors
- KwdEn :
- Animals, Anti-Bacterial Agents (administration & dosage), Anti-Bacterial Agents (adverse effects), Anti-Bacterial Agents (chemistry), Anti-Bacterial Agents (pharmacology), Bacteria (drug effects), Bacteria (growth & development), Bacterial Infections (drug therapy), Biofilms (drug effects), Biofilms (growth & development), Cell Membrane (drug effects), Disease Models, Animal, Drug Evaluation, Preclinical, Drug Resistance, Multiple, Bacterial, Membrane Potentials (drug effects), Microbial Viability (drug effects).
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents.
- chemical , adverse effects : Anti-Bacterial Agents.
- chemical , chemistry : Anti-Bacterial Agents.
- chemical , pharmacology : Anti-Bacterial Agents.
- drug effects : Bacteria, Biofilms, Cell Membrane, Membrane Potentials, Microbial Viability.
- drug therapy : Bacterial Infections.
- growth & development : Bacteria, Biofilms.
- Animals, Disease Models, Animal, Drug Evaluation, Preclinical, Drug Resistance, Multiple, Bacterial.
Abstract
The global prevalence of antibiotic resistance and the threat posed by drug-resistant superbugs are a leading challenge confronting modern medicine in the 21st century. However, the progress on the development of novel antibiotics to combat this problem is severely lagging. A more concerted effort to develop novel therapeutic agents with robust activity and unique mechanisms of action will be needed to overcome the problem of drug resistance. Furthermore, biofilm forming bacteria are known to be increasingly resistant to the actions of antibiotics and are a leading cause of mortality or morbidity in nosocomial infections. Bisphosphocins (also scientifically known as nubiotics) are novel small protonated deoxynucleotide molecules, and exert their antibacterial activity by depolarization of the bacterial cell membrane, causing bacterial cell death. Bisphosphocins may represent an effective weapon against antibiotic-resistant and biofilm-forming pathogenic bacteria. Preclinical efficacy studies in animals have shown that the compounds are safe and, efficacious against various bacterial infections, including drug-resistant pathogens. In vitro biochemical analysis confirmed that the bactericidal activity of bisphosphocins is mediated by depolarization of the bacterial cell membrane, and these compounds are better able to penetrate through bacterial biofilm and kill the biofilm encased bacteria. This article will cover the structure, mode of action, safety, efficacy and the current state of development of bisphosphocins. Together, the information presented here will present a strong case for bisphosphocins to be considered for use as new weapons to complement the existing arsenal of antimicrobial drugs and as a first line defence against drug-resistant and biofilm-forming bacteria.
DOI: 10.2217/fmb.15.70
PubMed: 26597426
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000596
- to stream PubMed, to step Curation: 000596
- to stream PubMed, to step Checkpoint: 000596
- to stream Ncbi, to step Merge: 001D85
- to stream Ncbi, to step Curation: 001D85
- to stream Ncbi, to step Checkpoint: 001D85
- to stream Main, to step Merge: 000810
- to stream Main, to step Curation: 000809
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.</title>
<author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P" last="Wong">Jonathan P. Wong</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Research & Development Canada, Suffield Research Center, Ralston, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Defence Research & Development Canada, Suffield Research Center, Ralston, Alberta</wicri:regionArea>
<wicri:noRegion>Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ditullio, Paul" sort="Ditullio, Paul" uniqKey="Ditullio P" first="Paul" last="Ditullio">Paul Ditullio</name>
<affiliation wicri:level="2"><nlm:affiliation>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Parkinson, Steve" sort="Parkinson, Steve" uniqKey="Parkinson S" first="Steve" last="Parkinson">Steve Parkinson</name>
<affiliation wicri:level="2"><nlm:affiliation>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:26597426</idno>
<idno type="pmid">26597426</idno>
<idno type="doi">10.2217/fmb.15.70</idno>
<idno type="wicri:Area/PubMed/Corpus">000596</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000596</idno>
<idno type="wicri:Area/PubMed/Curation">000596</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000596</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000596</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000596</idno>
<idno type="wicri:Area/Ncbi/Merge">001D85</idno>
<idno type="wicri:Area/Ncbi/Curation">001D85</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001D85</idno>
<idno type="wicri:Area/Main/Merge">000810</idno>
<idno type="wicri:Area/Main/Curation">000809</idno>
<idno type="wicri:Area/Main/Exploration">000809</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria.</title>
<author><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P" last="Wong">Jonathan P. Wong</name>
<affiliation wicri:level="1"><nlm:affiliation>Defence Research & Development Canada, Suffield Research Center, Ralston, Alberta, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Defence Research & Development Canada, Suffield Research Center, Ralston, Alberta</wicri:regionArea>
<wicri:noRegion>Alberta</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ditullio, Paul" sort="Ditullio, Paul" uniqKey="Ditullio P" first="Paul" last="Ditullio">Paul Ditullio</name>
<affiliation wicri:level="2"><nlm:affiliation>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Parkinson, Steve" sort="Parkinson, Steve" uniqKey="Parkinson S" first="Steve" last="Parkinson">Steve Parkinson</name>
<affiliation wicri:level="2"><nlm:affiliation>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Lakewood-Amedex Inc., 3030 University Pkwy, Sarasota, FL 34243</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Future microbiology</title>
<idno type="eISSN">1746-0921</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anti-Bacterial Agents (administration & dosage)</term>
<term>Anti-Bacterial Agents (adverse effects)</term>
<term>Anti-Bacterial Agents (chemistry)</term>
<term>Anti-Bacterial Agents (pharmacology)</term>
<term>Bacteria (drug effects)</term>
<term>Bacteria (growth & development)</term>
<term>Bacterial Infections (drug therapy)</term>
<term>Biofilms (drug effects)</term>
<term>Biofilms (growth & development)</term>
<term>Cell Membrane (drug effects)</term>
<term>Disease Models, Animal</term>
<term>Drug Evaluation, Preclinical</term>
<term>Drug Resistance, Multiple, Bacterial</term>
<term>Membrane Potentials (drug effects)</term>
<term>Microbial Viability (drug effects)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-Bacterial Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Bacteria</term>
<term>Biofilms</term>
<term>Cell Membrane</term>
<term>Membrane Potentials</term>
<term>Microbial Viability</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bacterial Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="growth & development" xml:lang="en"><term>Bacteria</term>
<term>Biofilms</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Disease Models, Animal</term>
<term>Drug Evaluation, Preclinical</term>
<term>Drug Resistance, Multiple, Bacterial</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The global prevalence of antibiotic resistance and the threat posed by drug-resistant superbugs are a leading challenge confronting modern medicine in the 21st century. However, the progress on the development of novel antibiotics to combat this problem is severely lagging. A more concerted effort to develop novel therapeutic agents with robust activity and unique mechanisms of action will be needed to overcome the problem of drug resistance. Furthermore, biofilm forming bacteria are known to be increasingly resistant to the actions of antibiotics and are a leading cause of mortality or morbidity in nosocomial infections. Bisphosphocins (also scientifically known as nubiotics) are novel small protonated deoxynucleotide molecules, and exert their antibacterial activity by depolarization of the bacterial cell membrane, causing bacterial cell death. Bisphosphocins may represent an effective weapon against antibiotic-resistant and biofilm-forming pathogenic bacteria. Preclinical efficacy studies in animals have shown that the compounds are safe and, efficacious against various bacterial infections, including drug-resistant pathogens. In vitro biochemical analysis confirmed that the bactericidal activity of bisphosphocins is mediated by depolarization of the bacterial cell membrane, and these compounds are better able to penetrate through bacterial biofilm and kill the biofilm encased bacteria. This article will cover the structure, mode of action, safety, efficacy and the current state of development of bisphosphocins. Together, the information presented here will present a strong case for bisphosphocins to be considered for use as new weapons to complement the existing arsenal of antimicrobial drugs and as a first line defence against drug-resistant and biofilm-forming bacteria.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>États-Unis</li>
</country>
<region><li>Floride</li>
</region>
</list>
<tree><country name="Canada"><noRegion><name sortKey="Wong, Jonathan P" sort="Wong, Jonathan P" uniqKey="Wong J" first="Jonathan P" last="Wong">Jonathan P. Wong</name>
</noRegion>
</country>
<country name="États-Unis"><region name="Floride"><name sortKey="Ditullio, Paul" sort="Ditullio, Paul" uniqKey="Ditullio P" first="Paul" last="Ditullio">Paul Ditullio</name>
</region>
<name sortKey="Parkinson, Steve" sort="Parkinson, Steve" uniqKey="Parkinson S" first="Steve" last="Parkinson">Steve Parkinson</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000809 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000809 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:26597426 |texte= Bisphosphocins: novel antimicrobials for enhanced killing of drug-resistant and biofilm-forming bacteria. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26597426" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonCanadaV1
This area was generated with Dilib version V0.6.29. |